Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS

Cancer-killing viruses show promise — and draw billion-dollar investment

Encouraging trial results spur interest from researchers and drug giants.
  1. Heidi Ledford
    View author publications

    You can also search for this author in PubMed  Google Scholar

Pharmaceutical giant Johnson & Johnson announced on 2 May that it would pay up to US$1 billion to acquire a company that makes cancer-killing viruses. It was a striking show of support for a still-unproven treatment, but the bid is just the latest sign that industry and academics are warming to the approach.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 557, 150-151 (2018)

doi: https://doi.org/10.1038/d41586-018-05104-1

References

  1. Andtbacka, R. H. I., et al. J. Clin. Oncol. 33, 2780-2788 (2015)

    Google Scholar 

  2. Ribas, A. et al. Cell 170, 1109-1119 (2017)

    Article  PubMed  CAS  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links